Scholarly article on topic 'A Paired RNAi and RabGAP Overexpression Screen Identifies Rab11 as a Regulator of β-Amyloid Production'

A Paired RNAi and RabGAP Overexpression Screen Identifies Rab11 as a Regulator of β-Amyloid Production Academic research paper on "Biological sciences"

Share paper
Academic journal
Cell Reports
OECD Field of science

Abstract of research paper on Biological sciences, author of scientific article — Vinod Udayar, Virginie Buggia-Prévot, Rita L. Guerreiro, Gabriele Siegel, Naresh Rambabu, et al.

Summary Alzheimer’s disease (AD) is characterized by cerebral deposition of β-amyloid (Aβ) peptides, which are generated from amyloid precursor protein (APP) by β- and γ-secretases. APP and the secretases are membrane associated, but whether membrane trafficking controls Aβ levels is unclear. Here, we performed an RNAi screen of all human Rab-GTPases, which regulate membrane trafficking, complemented with a Rab-GTPase-activating protein screen, and present a road map of the membrane-trafficking events regulating Aβ production. We identify Rab11 and Rab3 as key players. Although retromers and retromer-associated proteins control APP recycling, we show that Rab11 controlled β-secretase endosomal recycling to the plasma membrane and thus affected Aβ production. Exome sequencing revealed a significant genetic association of Rab11A with late-onset AD, and network analysis identified Rab11A and Rab11B as components of the late-onset AD risk network, suggesting a causal link between Rab11 and AD. Our results reveal trafficking pathways that regulate Aβ levels and show how systems biology approaches can unravel the molecular complexity underlying AD.

Academic research paper on topic "A Paired RNAi and RabGAP Overexpression Screen Identifies Rab11 as a Regulator of β-Amyloid Production"



Cell Reports


A Paired RNAi and RabGAP Overexpression Screen Identifies Rab11 as a Regulator of ß-Amyloid Production

Vinod Udayar,1'2'3 4 Virginie Buggia-Prevot,6 Rita L. Guerreiro,7,13 Gabriele Siegel,12 Naresh Rambabu,8 Amanda L. Soohoo,9 Moorthi Ponnusamy,8 Barbara Siegenthaler,12 Jitin Bali,12 3 AESG,7 Mikael Simons,1011 Jonas Ries,12 Manojkumar A. Puthenveedu,9 John Hardy,713 Gopal Thinakaran,6 and Lawrence Rajendran1,2,3,5,*

1Systems and Cell Biology of Neurodegeneration, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland 2Division of Psychiatry Research, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland 3Graduate Program of the Zurich Neuroscience Center, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland 4Erasmus Mundus Joint Doctorate Program, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland

5Graduate Program of the Zurich Center for Integrative Human Physiology, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland 6Departments of Neurobiology, Neurology and Pathology, The University of Chicago, Chicago, IL 60637, USA 7Alzheimer's Exome Sequencing Group, University College London, London WC1E 6BT, UK

8Raise.Rural Foundation for Promoting Research Awareness in Student Environment in Rural India, 60045 Chennai, India

9Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA 15213, USA

10Department of Neurology, University of Gottingen, 37075 Gottingen, Germany

"Max-Planck Institute for Experimental Medicine, 37075 Göttingen, Germany

12Cell Biology and Biophysics, European Molecular Biology Laboratory, 69117 Heidelberg, Germany

13Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK 'Correspondence:

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.


Alzheimer's disease (AD) is characterized by cerebral deposition of b-amyloid (Ab) peptides, which are generated from amyloid precursor protein (APP) by b- and g-secretases. APP and the secretases are membrane associated, but whether membrane trafficking controls Ab levels is unclear. Here, we performed an RNAi screen of all human Rab-GTPases, which regulate membrane trafficking, complemented with a Rab-GTPase-activating protein screen, and present a road map of the membrane-trafficking events regulating Ab production. We identify Rab11 and Rab3 as key players. Although retromers and ret-romer-associated proteins control APP recycling, we show that Rab11 controlled b-secretase endosomal recycling to the plasma membrane and thus affected Ab production. Exome sequencing revealed a significant genetic association of Rab11A with late-onset AD, and network analysis identified Rab11A and Rab11B as components of the late-onset AD risk network, suggesting a causal link between Rab11 and AD. Our results reveal trafficking pathways that regulate Ab levels and show how systems biology approaches can unravel the molecular complexity underlying AD.


Alzheimer's disease (AD) is the most common form of dementia and is characterized by the cerebral deposition of ß-amyloid (Aß) peptides in the form of amyloid plaques (De Strooper, 2010; Fri-soni et al., 2011). The amyloid cascade hypothesis postulates that Aß peptides trigger a series of pathological events leading to neurodegeneration (Huang and Mucke, 2012; Selkoe, 2011b). Aß peptides are liberated from the transmembrane amyloid precursor protein (APP) by the sequential actions of ß-secretase and g-secretase (Thinakaran and Koo, 2008; Willem et al., 2009). ß-secretase activity is conferred by a transmembrane aspartyl protease, also termed BACE1 (ß-site APP-cleaving enzyme 1) (Vassar et al., 1999), whereas g-secretase is a multimeric transmembrane protein complex composed of presenilin-1 (PS1)/PS2, nicastrin, Aph-1, and PEN-2 (Annaert and De Strooper, 2002; Selkoe and Wolfe, 2007). Familial mutations in APP, PS1, or PS2 that increase the production of the amyloidogenic Aß42 peptide have been associated with early-onset AD (Borchelt et al., 1996; Duff et al., 1996). However, there is only limited insight into the cause of late-onset AD (LOAD), which contributes to more than 95% of cases. Genetic modifiers of LOAD may also regulate Aß production, raising the possibility that genes regulating APP metabolism might impact the risk for AD (Andersen et al., 2005; Rogaeva et al., 2007; Selkoe, 2011a).

Several lines of evidence support an important role for membrane trafficking in the amyloidogenic processing of APP


and hence in AD pathogenesis (Rajendran and Annaert, 2012; Thinakaran and Koo, 2008). APP and BACE1 are transmembrane proteins that are synthesized in the endoplasmic reticulum (ER), matured in the Golgi complex, and then transported to the plasma membrane and into endosomes via endocytosis (Small and Gandy, 2006; Thinakaran and Koo, 2008). The endolysoso-mal compartment has been implicated as one of the major sites for Aß generation (Cataldo et al., 2000; Haass et al., 1992; Koo and Squazzo, 1994). Recent work has revealed that BACE1 cleavage of APP occurs predominantly in early endosomes, and endocytosis of APP and BACE1 is essential for ß cleavage of APP, and Aß production (Kinoshita et al., 2003; Rajendran et al., 2006; Sannerud et al., 2011). The pH of endosomes (pH 4.0-5.0) is optimal for BACE1 activity, which also explains the requirement for endocytosis (Kalvodova et al., 2005; Vassar et al., 2009). In contrast, a-secretase cleavage of APP, which precludes Aß production, occurs at the plasma membrane (Lichtenthaler, 2011). Components of the g-secretase complex are also synthesized in the ER, but their assembly and maturation require the coordinated regulation of the ER-Golgi-recycling circuit (Spasic and Annaert, 2008).

We previously showed that ß cleavage of APP occurs in a Rab5-EEA1-positive membrane compartment and that endocytosis is essential for Aß generation (Rajendran et al., 2006). Targeting a transition-state BACE1 inhibitor to endosomes inhibited Aß production in cultured cells and mice (Rajendran et al., 2008). Interestingly, proteins that belong to the retromer family, which transport cargo from early endosomes to the Golgi, have also been implicated in AD (Rogaeva et al., 2007; Small et al., 2005). These AD risk genes regulate the residency of APP and BACE1 in the early endosomal compartment, therefore regulating Aß generation (Siegenthaler and Rajendran, 2012). Similarly, proteins of the GGA family have been shown to traffic BACE1 from endosomes to the Golgi, and their depletion led to increased amyloidogenic processing of APP (He et al., 2005; Tesco et al., 2007; von Arnim et al., 2006). Although APP is known to be routed from endosomes to Golgi via the retromer and retromer-associated proteins including SORL1 and VPS26 (Andersen et al., 2005; Morel et al., 2013; Small and Gandy, 2006; Rogaeva et al., 2007; Small et al., 2005; Siegenthaler and Rajendran, 2012), nothing much is known about BACE1 recycling from endosomes. A better understanding of the specific trafficking mechanisms involved in Aß production will thus provide further insights into disease pathogenesis and potentially provide novel therapeutic strategies for treating this currently un-treatable disease.

Rab GTPases regulate many aspects of membrane protein trafficking, acting as membrane organizers on cellular compartments that mediate vesicular trafficking and aid in vesicle fusion (Seabra et al., 2002). They regulate vesicular trafficking both in the biosynthetic and endocytic routes, enabling cargo sorting within the different membrane compartments (Zerial and McBride, 2001). Rab GTPases switch between an inactive GDP-bound form and an active GTP-bound form, which enables vesicular fusion (Stenmark and Olkkonen, 2001). Although GDP-GTP exchange is mediated by Rab-specific GTP exchange factors (GEFs), GTP hydrolysis is achieved by the GTPase-acti-vating proteins (GAPs) (Barr and Lambright, 2010). In humans,

there are 60 Rab proteins and 39 RabGAPs. Overexpression of RabGAPs depletes the active form of Rab proteins and increases the inactive, GDP-bound form, thereby preventing their normal function (Yoshimura et al., 2007). Here, we systematically analyzed the role of the cell's major membrane-trafficking processes in Ap production by the combined use of RNAi-mediated silencing of all Rab GTPase proteins and an overexpression screen of the RabGAPs.


Development of a Multiplexing Platform to Quantitatively Assay sAPPp and Ap Levels

We first developed a multiplexing assay to quantitatively screen for Ap and soluble ectodomain of APP p (sAPPp), the two products of the amyloidogenic processing of APP (Figure 1A), from a single sample. Simultaneous measurements of Ap and sAPPp from a single sample in the same well would indicate whether a "hit" affected the p cleavage of APP (changing sAPPp levels) or the g cleavage/fate of Ap (changing Ap levels) (Figure 1B). Thus, intermeasurement variations are avoided, which increases the sensitivity and signal-to-noise ratio allowing high-throughput measurements. We used an electrochemiluminescence (ECL) assay platform because it provides high sensitivity and robust signal detection. In each well of a 384-well plate, one spot of anti-Ap40 and one of anti-sAPPp were separately spotted (Figure 1C). Two other spots were coated with BSA for background and nonspecific binding controls. Upon binding to the analytes in the samples, electrochemical signals from the rutheniumlabeled respective secondary antibodies were detected through an image-based capture. Because the captured antibodies are spatially positioned at distinct spots in the well, the values corresponded to the amount of the analyte bound to the specific capture antibody. As a proof of principle, we studied the binding of synthetic Ap40 and recombinant sAPPp in the same well. We incubated different concentrations of synthetic Ap peptides in the assay plate and found a linear dependency of the signal to the amount of peptide used at concentrations lower than 50 ng/ml. At concentrations above 50 ng/ml, we observed saturation (Figure 1D). Similar saturation kinetics was observed with recombinant sAPPp protein, suggesting that this system perfectly recapitulates binding reactions. When only Ap was added to the well, background signals were observed for sAPPp, and vice versa. When both Ap and sAPPp were added in the same well, specific signals were detected (Figure 1D), demonstrating a high degree of specificity and no cross-reactivity between the two analytes. In addition, ECL detection allowed us to detect concentrations as low as 10-100 pg of Ap and sAPPp.

We then proceeded to see if Ap and sAPPp could be measured from cultured cells and neurons from transgenic mice. Both Ap and sAPPp could be measured from HEK and HeLa cells stably expressing the pathogenic Swedish mutant of APP, which causes familial early-onset AD (Figure 1E). Conditioned medium collected at different times shows that both Ap and sAPPp gradually accumulated in a time-dependent manner (Figure 1E). Increase in the volume of the conditioned supernatants produced a linear increase in the measurements demonstrating assay robustness (Figures S1A and S1B). We could also quantify


Figure 1. A Multiplexing Platform for the Detection of Amyloidogenic Processing of APP

(A) Schematic of the screen.

(B) Cartoon of APP cleavage by ß- and g-secretases.

(C) Cartoon of ECL detection system.

(D) Incubation of synthetic Aß (Aß40, black) and recombinant sAPPß (red) either individually or together gives specific signals.

(E) Supernatants from HEK (HEK-sweAPP) or HeLa cells overexpressing the Swedish mutant of APP (HeLa-sweAPP) and primary cortical neurons from Arc/sweAPP Tg analyzed for Aß (black) and sAPPß (white for HEK and HeLa; gray for the cortical neurons) levels.

(F and G) Specificity of the ECL-multiplex assay platform. Signals for Aß40 (black) and WT sAPPß (gray) from conditioned medium of HEK-WTAPP (F) or HEK-sweAPP (G) analyzed with capture antibodies specific for Aß and WT sAPPß.

(H and I) Signals for Aß40 (black) and swe-sAPPß (gray) from conditioned medium of HEK-WTAPP cells (H) or HEK-sweAPP cells (I). Error bars indicate SD. See also Figures S1A and S1B.

sAPPp and Ap in cortical neurons from mice expressing human APP with Arctic/Swedish (Arc/Swe) mutations (Figure 1E). Sample-swapping (Figure 1F) experiments showed that no significant signal was observed for the p-cleaved ectodomain of Swedish APP (sAPPpsw) when measured with the plate coated in capture antibodies, which recognized the p-cleaved ectodo-main of wild-type (WT) APP (sAPPpWT). Similarly, no signal was obtained for sAPPp when we swapped the sAPPpWT super-

natants on the sAPPßsw-coated plates. However, robust signals for Aß were detected in all conditions. Thus, the assay is highly specific for both Aß and sAPPß.

RNAi Screen of Human Rab Proteins Identifies Proteins Involved in Aß and sAPPß Production

To study the role of all human Rab proteins in the regulation of amyloidogenic APP processing, we first performed an RNAi


screen (Table S1) in cells that robustly produce Ap and sAPPp (Rajendran et al., 2006, 2008) and assayed these products using the multiplexing ECL assay system (Figures 2A and 2B). We included APP, BACE1, and Pen2 (a subunit of the g-secretase) as positive controls. As expected, silencing of APP and BACE1 decreased both Ap and sAPPp levels, whereas silencing of Pen2 decreased Ap levels, but not sAPPp levels (Figures 2A and 2B), further validating the assay. Quantification was based on the ECL counts, normalized to the cell viability counts, and relative to that of the scrambled control (medium GC containing siRNA oligo [MedGC]). Apart from Rab36, silencing of the other Rab proteins did not significantly alter cell viability (Figure S1C). The screen identified Rabs that significantly decreased both Ap and sAPPp (Figures 2A and 2B), including Rab3A, Rab11A, Rab36, and Rab17 (Figures S2A and S2B). Rab36, a GTPase involved in late endosome positioning, was a top hit in the screen, decreasing both Ap and sAPPp (Figure 2C). A secondary validation screen reproduced all the selected hits (Figure S2C). Knockdown efficiency of the relevant genes was confirmed by RT-PCR (Figure S2D). Although our analysis accounts for toxicity, and quantifies Ap and sAPPp as a relative count of viable cells, Rab36 depletion was consistently toxic in all the screens (Figure S1C). Therefore, we removed it from further analysis.

Rab11A, the major Rab protein involved in the slow recycling of cargo proteins from early endosomes to the cell surface (Son-nichsen et al., 2000), was the second top hit in our analysis. In addition, silencing of the isoform, Rab11B, also reduced Ap levels (Figure 2A). Interestingly, all the isoforms of Rab3, except Rab3C, decreased both Ap and sAPPp levels. Rab3 proteins are involved in synaptic function (Schluteret al., 2004) and in the fast axonal transport of APP (Szodorai et al., 2009). Silencing of Rab3A and Rab3B decreased overall APP levels, suggesting that Rab3 plays a role in the trafficking and maintenance of APP levels (Figure S2E).

Silencing of Rab44, Rab6A, and Rab10 decreased Ap levels without affecting sAPPp (Figure 2C), implying that these GTPases affect either g-secretase cleavage or the fate of Ap. Interestingly, knockdowns of several Rabs also increased both sAPPp and Ap levels. To understand how these trafficking pathways contributed to both Ap and sAPPp levels, we plotted the normalized values of Ap and sAPPp from the screen in a 2D plot and observed a largely correlative curve for both the values, indicating that the Rab proteins responsible for regulating p cleavage are also responsible for controlling Ap levels and that any perturbation at the level of BACE1 cleavage of APP is the rate-limiting step in Ap production (Figure 2D).

RabGAP-Overexpression Screen Identifies Overlapping Hits with the Rab RNAi Screen

Because RNAi can have off-target effects leading to false-positive results, we complemented our RNAi screen with an overexpression screen of all 39 RabGAPs in the human genome, which suppress Rab function by accelerating the hydrolysis of GTP. In this screen, we overexpressed each RabGAP in the same cellular system used for the RNAi screen and quantitatively measured Ap, sAPPp levels, and cell viability (Figures 3 and S1D). Many RabGAPs were found to affect sAPPp and Ap levels (Figure 3). RN-TRE, a GAP that has previously been shown to

affect amyloidogenic processing of APP (Ehehalt et al., 2003), reduced both Ap and sAPPp. TBC1D10B, a GAP for Rab35, Rab27A, Rab22A, Rab31, and Rab3A, decreased both Ap and sAPPp (Frasa et al., 2012). However, only Rab3A silencing via RNAi decreased Ap and sAPPp (Figures 2 and 3). EVI5, a RabGAP for Rab11 (Frasa et al., 2012; Laflamme et al., 2012), decreased both Ap and sAPPp. In addition, one other RabGAP for Rab11, namely TBC1D15, decreased both Ap and sAPPp. Intriguingly, TBC1D14, which alters Rab11 localization and subsequently delays recycling of transferrin to the plasma membrane (Longatti et al., 2012), decreased Ap levels (Figure 3C). These results independently identified Rab11 as an important regulator of sAPPp and Ap production.

Epistasis Mini Array Profiling Identifies Distinct Trafficking Routes

We next analyzed whether the identified Rabs regulated Ap production through the same trafficking pathway or through distinct mechanisms. To this end, we performed an epistasis mini array profiling (EMAP) screen (Schuldiner et al., 2005) wherein we silenced all the hits against all the hits in a 14 x 14 matrix to determine whether a combined knockdown gives rise to an aggravating (noninteracting) or alleviating (interacting) pheno-type (i.e., p cleavage of APP). Here, again, single knockdowns of either Rab3A or Rab11A decreased sAPPp levels (Figure S3). However, when they were silenced together, a further decrease (an aggravating phenotype) was observed, which indicates that Rab3Aand Rab11A act independently and contribute to p cleavage via distinct trafficking routes. Most of the genes that were identified as hits did not interact with each other, with the exception that a double knockdown of Rab10/Rab23 or Rab10/Rab25 showed an alleviating phenotype, suggesting that these Rabs regulate the same membrane-trafficking pathways.

Validation of Rab11A as a Hit

Because Rab11A was identified as one of the strongest hits in both the RNAi screen and the RabGAP screen, we independently validated this finding in a different cellular model. siRNA-medi-ated silencing of Rab11A in HEK cells stably expressing WTAPP led to a strong reduction of both Ap and sAPPp levels (Figure S4A), similar to the effect observed upon silencing of Rab11A in HeLa cells stably expressing sweAPP (Figure 4A). Consistent with this, western blotting analysis with APP C terminus antibodies revealed a strong reduction in p-C-terminal fragment (CTF) levels (C99) with an increase in a-CTF levels (Figure 4B). This suggests that Rab11A silencing markedly affected p cleavage of APP and also Ap levels. Western blotting with Rab11A antibodies showed that Rab11A silencing efficiently knocked down the protein (Figure 4B) (with >90% efficiency). In addition, Rab11A silencing led to a decrease in all three species of Ap (Ap38, Ap40, and Ap42) (Figure 4C) and reduced amyloid levels in the cell lysates, suggesting that Rab11A regulates Ap production rather than secretion (Figure S4B). Silencing of Rab11A using four different siRNAs singly also led to a decrease in Ap without affecting cell viability, thus demonstrating the specificity of the observed effect (Figure 4D). All siRNAs against Rab11A also silenced Rab11A expression (Figure 4D, inset).

30 (D "O O

OI G3 01 I


73 73 737 >> >>

03 CD 03 0:

73 73 73 73 73 73 73 73 >>>>>>>>

C0 03 03CD03030303

73 73 7)73 73 73 >>>>>>

CD CO CD 03 03 TO

73 73 73 73 73 73 73 W 73 73 > >0 >>>>>>>>> m "0 ^ 03 03 03 03 03 03CDO03Z~0 I O 03 03 > £

73 73 73 73 73 73 73 73 U3 > >>>>>>>>>"0 03CDCDCD03 03 03 03OT)



1 Ion S +|¡

'™8g° I


ni fl>

ECL values normalized to cell viabilty and relative to control


RAB6C RAB7A RAB7B RAB8A RAB8B RAB9A RAB9B RAB10 RAB11A RAB11B RAB12 RAB13 RAB14 RAB15 ' RAB17 ' RAB18 ' RAB19 ' RAB20 ' RAB21 ' RAB22A RAB22B/RAB31 RAB23 . RAB24 RAB25 ] RAB26 ' RAB27A RAB27B _ RAB28 | RAB30 " RAB32 ] Rab33A RAB33B RAB34 " RAB35 RAB36 | RAB37 | RAB38 RAB39 | RAB40A RAB40B RAB40C ' RAB41 | RAB42 RAB43 " RAB44

To further validate these results, we employed a different strategy to interfere with Rab11 function. Because Rab proteins exist in both a GTP-bound and GDP-bound form, we overexpressed the GDP-locked (dominant negative; DN) mutant forms of Rab11A (the ubiquitously expressed isoform) and Rab11B (the isoform highly expressed in neurons) in cells to phenocopy the effect of Rab11 silencing. Similar to silencing of Rab11A, overexpression of Rab11ADN reduced Ap and sAPPp levels significantly. Overexpression of Rab11B DN (which would also interfere with the function of WT Rab11) also significantly reduced Ap and sAPPp levels (Figure 4E).

Finally, we assessed the effect of silencing the expression of evolutionarily conserved Rab11 family-interacting proteins on p cleavage of APP in the cells (Lindsay and McCaffrey, 2002). Knockdown of four of the five FIP family proteins (Shiba et al., 2006), with the exception of Rab11FIP1 (retromer-like), decreased sAPPp levels (Figure 4F). Thus, not only Rab11 but also Rab11-interacting proteins, which were identified as Rab11-effector proteins, reduced p cleavage of APP.

Rab11 Silencing in Primary Neurons from WT and APP Transgenic Mice Reduces Ab Levels

We next studied if Rab11 also regulated Ap production in the neuronal context. Silencing Rab11Aand Rab11B in primary neurons isolated from APP transgenic mice significantly decreased both sAPPp and Ap levels (Figure 4G). Both RT-PCR and western blotting analysis show efficient silencing of Rab11A and Rab11B (Figures S4C, S4D, and 4H; Table S2). Knockdown of Rab11A and Rab11B in primary neurons isolated from WT mice again reduced Ap (both Ap40 and Ap42) levels (Figures 4I and 4J). Moreover, silencing either Rab11A or Rab11B also significantly decreased Ap levels (Figure S4E). Thus, Rab11 is crucial for p cleavage and Ap generation.

Rab11 Controls Membrane Trafficking of BACE1

We hypothesized that Rab11 must regulate either at the level of APP or at the level of BACE1. Rab11 silencing or Rab11A DN expression did not affect the total cellular levels of APP or BACE1 (Figures 4B and S4F, respectively). To analyze protein localization, we performed live-cell imaging of cells transfected with either APP-YFP or BACE1-YFP using a wide-field microscope maintained under a temperature-controlled environment. BACE1-YFP prominently localized to the perinuclear endocytic-recycling compartment (ERC) and was also found in numerous highly motile vesicular and tubular structures dispersed throughout the cell (Figure 5A; Movie S1). Inspection of individual carriers revealed rapid transport of tubulo-vesicular structures along a curvy linear trajectory, suggesting active transport along microtubules (Movie S1). Indeed, brief treatment of cells with the


microtubule-disrupting reagent nocodazole inhibited dynamic transport of BACE1 and induced the formation of enlarged immobile vesicles (data not shown). The distribution and dynamics of BACE1 trafficking, but not of APP, were markedly altered by expression of Rab11AS25N, the DN mutant of Rab11 (Rab11A DN) (Figure 5A; Movies S1 and S2). The length of the BACE1-positive tubular carriers emanating from the ERC was significantly enhanced by Rab11A DN overexpression but remained highly dynamic, suggesting that GTPase activity of Rab11 is involved in the fission of BACE1 tubular carriers and/or their tethering and fusion with the target.

Rab11 GTPase is involved in recycling many cargos from the ERC, including the recycling endosome marker transferrin receptor (TfR) (Sonnichsen et al., 2000). TfR as well as internalized transferrin become associated with a distinct tubular network in cells expressing Rab11 DN (Choudhury et al., 2002; Wilcke et al., 2000). To address whether BACE1 follows the recycling route from recycling endosomes, we first checked whether BACE1 colocalizes with TfR. BACE1 significantly colocalized with TfR (Figure 5B). Not only the steady-state levels of TfR but also internalized transferrin colocalized with BACE1 in Rab11 compartments (data not shown). In control cells and those transfected with Rab11A WT, BACE1-YFP colocalized with TfR in the ERC as well as in numerous vesicles and short tubulo-vesicular carriers (Figure 5B). However, in cells expressing Rab11A DN, BACE1 and TfR were found in elongated tubular structures that emanated from the ERC (Figure 5B). Neither the prominent perinuclear localization of APP in the TGN nor the dynamics of APP-positive structures was disturbed by Rab11A DN expression (Figure 5A). Thus, BACE1 localization and trafficking are akin to that of TfR, which requires recycling via the Rab11-medi-ated pathway for transferrin internalization. Because Rab11 regulates the recycling of TfR through the slow recycling route, it may also regulate the recycling of BACE1, thus affecting both the cell surface as well as the early endosomal trafficking of BACE1.

Rab11 Affects the Recycling of BACE1

Because BACE1 accumulated in elongated tubulo-vesicular structures in cells expressing Rab11A DN, we hypothesized that under these conditions, BACE1 is unable to be trafficked to the plasma membrane and thus is unavailable for reinternal-ization to early endosomes, the site of Ap production. To test this, we performed two different experiments. First, we tested if Rab11A regulated cell surface levels of BACE1 using FLAG-tagged BACE1 (Figure S5A). Here, we used both FACS (fluorescence-activated cell sorting) as well as immunofluorescence on cells transfected with either control or Rab11A DN-expressing plasmids. Cells expressing Rab11A DN indeed displayed

Figure 2. RNAi Screen of Genome-wide Rabs Identifies Rabs Involved in Regulating the Levels of Ap and sAPPp

(A and B) Graph showing the levels of Ap (A) and sAPPp (B) from the Rab sIRNA screen. HeLa-sweAPP cells were transfected with Scrambled ollgo (negative control), or pooled siRNA against APP, BACE1, PEN2, and the 60 Rabs and assayed for Ap and sAPPp. Error bars indicate SEM.

(C) List of genes that had the strongest effect on Ap and sAPPp levels after siRNA-mediated silencing along with the Z score and t test values.

(D) 2D plot representing the levels of Ap and sAPPp from the Rabs siRNA screen. Positive controls APP, BACE1, and PEN2 are indicated in green, and negative control Scrambled is indicated in blue. Rabs silencing that led to the strongest decrease in both Ap and sAPPp is indicated in red. All statistics were performed using the two-tailed t tests and one-way ANOVA (Table S4).

See also Figures S1C, S2, and S3.


Figure 3. RabGAP Screen Identifies GAPs and Rabs in the Regulation of Aß and sAPPß Levels

(A) Graph showing the levels of Aß (black) and sAPPß (gray) after RabGAP plasmid overexpression. HeLa-sweAPP cells were transfected with plasmid expressing RabGAP fused with GFP or a plasmid expressing GFP (negative control) and assayed for Aß and sAPPß. Error bars indicate SEM.

(B) Graphs showing Z scores of the effects on sAPPß and Aß levels after RabGAP overexpression.

(C) Table showing RabGAPsthat had the strongest effect on Aß and/or sAPPß levels along with their cognate Rab(s). The asterisk (*) indicates that the TBC1D14 is not a GAP for Rab11 but has been shown to perturb the localization and function of Rab11 (Longatti et al., 2012).

See also Figure S1D.

reduced cell surface levels of BACE1 (Figures 6A and 6B). Similar results were obtained using imaging of cell surface-labeled BACE1 in HeLa (Figure 6C) and primary neurons (Figure 6D). Rab11A DN did not reduce the total levels of BACE1 (Figure S4F), in line with the observations that under Rab11A

DN-expressing conditions, BACE1 accumulates in the tubulo-vesicular compartments and is not rerouted to degradative compartments.

Next, we specifically looked at the effect of Rab11A in the recycling pool of BACE1 using a quantitative ratiometric assay


Figure 4. Rab11 Regulates BACE1 Cleavage of APP in Model Cell Lines and Primary Neurons from WT and APP Transgenic Mice

(A) HeLa-sweAPP cells were transfected with scrambled oligo (MEDGC, negative control) or pooled siRNA against APP and Rab11A and assayed for Ap (dark gray) and sAPPp (light gray). Error bars indicate SD.

(B) HeLa-sweAPP cells were transfected with scrambled oligo or pooled siRNA against Rab11A, and the lysates were assayed by western blotting as indicated.

(C) HeLa-sweAPP cells were transfected with scrambled oligo or pooled siRNAs against APP and Rab11A and assayed for Ap38 (light gray), Ap40 (dark gray), and Ap42 (black). Error bars indicate SEM.

(D) HeLa-sweAPP cells were transfected with scrambled oligo or pooled siRNA against APP, single siRNA (si1-si4) against Rab11A, and pooled siRNA against Rab11Aand assayed for Ap40 (dark gray) and cell viability (light gray), and the lysates were assayed by western blotting as indicated (inset). Error bars indicate SD.

(E) HeLa-sweAPP cells were transfected with PCDNA 3.1 (negative control), Rab11A DN, and Rab11B DN and assayed for Ap40 (dark gray) and sAPPp (light gray). Error bars indicate SEM.

(F) HeLa-sweAPP cells were transfected with scrambled oligo or pooled siRNA against APP, BACE1, and Rab11FIP1-Rab11FIP5 and assayed for sAPPp. Error bars indicate SEM.

(G-J) Silencing of Rab11 in primary neurons from APP transgenic and WT mice reduces p cleavage of APP and Ap levels.

(G) Rab11Aand Rab11B were silenced in primary cortical and hippocampal neurons isolated from APP transgenic mice expressing the Swedish mutation in APP, and the secreted levels of Ap and sAPPp were measured. The scrambled oligo was used as a negative control and siRNA targeting APP as positive control. Error bars indicate SD.

(H) Western blotting with Rab11A and GAPDH antibodies from control and Rab11-silenced primary neurons.

(I) Rab11A and Rab11B were silenced in primary cortical and hippocampal neurons isolated from WT mice, and the secreted levels of endogenous Ap40 and Ap42 were measured. The scrambled oligo was used as a negative control and siRNA targeting APP as positive control. Error bars indicate SD.

(J) Western blotting with Rab11A and GAPDH antibodies from control and Rab11-silenced primary WT neurons.

*p < 0.05, **p < 0.01, and ***p < 0.001 compared with scrambled MEDGC or PCDNA3.1. n.s., not significant. All statistics were performed using the two-tailed t tests. Similar significance was also observed with one-way ANOVA (Dunnett's a posteriori analysis) (Table S5). See also Figures S4A-S4E.


Figure 5. BACE1 Colocalizes with Rab11 Compartments, and Its Trafficking Is Altered upon Rab11 Dysfunction

(A) Live-cell Images of COS cells transfected with BACE1-YFP or YFP-APP along with empty vector (control) or Rab11ADN. Expression of Rab11ADN protein Is shown in the insets.

(B) COS cells were transiently cotransfected with BACE1-YFP (green) and empty vector, HA-tagged Rab11A WTor S25N DN mutant, and fixed and stained with HA (data not shown) and TfR antibodies (red) to label recycling endosomes. The colors in the first two panels are green for BACE1-YFP and red forTfR. Insets are the zoomed-in images of the corresponding images.

See also Figure S5A and Movies S1 and S2.

to measure recycling by differential labeling. To this end, cells were labeled with Alexa 647-conjugated M1 anti-FLAG for 30 min at 37°C, to allow antibodies to bind surface BACE1 and be internalized. After internalization, cells were incubated with Alexa 488-conjugated secondary antibodies for 30 min at 37°C, to detect internalized anti-FLAG-bound receptors that recycled to the surface. In the Rab11A DN-expressing cells, BACE1 recycling was significantly decreased, confirming that Rab11 functions to recycle BACE1 from the endosomes to the plasma membrane (Figure 6E). Quantitation of the fluorescence signal clearly revealed that the recycling pool of BACE1 is markedly decreased in cells expressing Rab11A DN. Two parallel controls were used: a surface control, where both incubations were performed at 4°C; and an endocytosis control, where the first incubation was at 37°C and the second at 4°C (Figure S5B). Cells without BACE1 did not show any labeling under these conditions. Together, these results suggest that vesicular trafficking regulated by Rab11 GTPase is critically important for the homeostatic regulation of BACE1 trafficking and Ap production in endocytic organelles.

Rab11 Genetic Variability in LOAD

We used exome-sequencing data from 170 neuropathologically assessed controls and 185 patients with LOAD to study if variants in Rab11A were associated with AD. Our results revealed a significant association of a variant in Rab11A (rs117150201; uncorrected p value = 0.01), thus establishing a potential association between Rab11 and AD (Table S3).

Network Analysis of GWAS Genes Linked to LOAD Identifies Rab11A and Rab11B as Interacting Proteins

To determine whether other genes linked with LOAD risk also acted via Rab11, we used protein-protein interaction (PPI) network analysis to study the interaction partners of proteins linked to LOAD risk. We used the protein products of top ten genes linked to LOAD (AlzGene; and created a two-level depth interactome of these proteins. In the cluster with Bin1, a risk gene that is strongly associated with LOAD risk, we identified both Rab11A and Rab11B and their interacting proteins, Rab11FIP1-Rab11FI5 (Figure S6). In our RNAi-based screen, Rab11A, Rab11B, and all the FIPs (except for FIP1) regulated Ap levels, further supporting the findings that the LOAD risk gene, Bin1, could contribute to amyloid production via Rab11. Interestingly, the Bin1 cluster also included Arf6, a known player in BACE1 endocytosis to early endosomal compartments (Sannerud et al., 2011) and GGA3, which regulates early endosomal residency of BACE1 (Tesco et al., 2007), further supporting the link between Bin1, Rab11 and BACE1 endocytosis and recycling. These results from this unbiased network analysis strongly link Rab11 to LOAD risk.

Rabs and Membrane-Trafficking Pathways in Amyloid Secretion

Using a systems approach, our screen also identified other regulatory active Rabs, and it provides insights into membrane-trafficking pathways that play crucial roles in amyloid production and secretion. This allowed us to present a comprehensive road map for APP processing (Figure 7). Most of the hits


were Rabs involved in the regulation of the trafficking either to or from early endosomes (Galvez et al., 2012; Pfeffer and Aivazian, 2004), confirming the critical role of early endosomes in Ap generation (Kinoshita et al., 2003; Koo and Squazzo, 1994; Rajendran et al., 2006; Small and Gandy, 2006). In addition to Rab11, several other Rabs were identified to also regulate Ap levels. Silencing of Rab2A, for instance, increased Ap and sAPPp levels (Figure 2), and the cognate GAP, TBC1D11, showed a similar effect (Figure 3). Rab2A is involved in the maintenance of Golgi structure and function. It interacts with the atypical protein kinase C (aPKC) (Tisdale, 2003) that positively regulates a cleavage of APP via a-secretase (Nitsch et al., 1993).

On the other side, Rab5C silencing significantly increased sAPPp and Ap, whereas the other Rab5 isoforms did not. Rab5C is involved in the endocytosis and recycling of cell surface molecules (Onodera et al., 2012). Silencing of Rab5C dramatically increased the cellular levels of APP (Figure S2E), which explains the increase in sAPPp and Ap.

The Rab proteins that have been implicated in exosome release, namely Rab27 and Rab35 (Hsu et al., 2010; Ostrowski et al., 2010), negatively regulated Ap and sAPPp levels (Figure 2). This is consistent with our previous work showing that very small amounts of Ap can be released via exosomal vesicles, and suggests that the exosomal pathway is connected to an intracellular degradation mechanism and that inhibition of the exosomal pathway reroutes the cargo for effective secretion.


To rule out potential off-target effects of the RNAi screen, we complemented it with five independent experimental conditions: (1). The first was an unbiased Rab-GAP overexpression screen; a paired RNAi screen (of all human Rab GTPases) and an overexpression screen (of RabGAPs) were performed; (2) Rab11 DN phenocopied the effect of RNAi of Rab11. (3) All four different siRNAs against Rab11 decreased Ap levels. (4) Rab11 RNAi had the same effect in many different cells, including primary neurons. Finally, (5) silencing Rab11-associated proteins such as EHD or FIPs produced similar effect.

The results from our RNAi, RabGAP, and EMAP screens provide a valuable list of all the human Rab proteins that affect Ap and sAPPp levels and their nature of interaction. We also silenced different isoforms of a particular Rab by means of RNAi, and indeed, in many cases, we found isoform-specific effects on Ap levels.

Silencing of Rab4A, Rab6A, and Rab10 decreased only Ap. Conversely, silencing of Rab8A, Rab25, Rab14, and Rab34 significantly increased only Ap. Such Ap-specific effects are likely the result of either an altered g-secretase cleavage of APP or a change in secretion and/or degradation of the produced Ap. Of particular interest is Rab8, which increased Ap levels when depleted in cells. Rab8 is involved in various physiological functions such as exocytosis and cilia formation. Interestingly, expression of a mutant PS1 (A260V) in PC12 cells dramatically decreased Rab8 levels, thus affecting trafficking via Golgi (Kametani et al., 2004). We also identified some hits that specifically decreased sAPPp levels without affecting Ap. Although this at first seems counterintuitive, it implies the possi-

bility that specific Rabs play a role in the release/secretion of sAPPp without affecting the processing of APP. However, we see a clear overall correlation of sAPPp and Ap, which suggests two things: (1) p cleavage is rate limiting and thus determines cellular and secreted Ap levels, or (2) compartments that define p cleavage are also involved in g cleavage of APP to generate Ap (Kaether et al., 2006; Rajendran et al., 2006).

We identified Rab11 as a main regulator of APP processing. Both by ECL assays and through western blotting to study APP processing, we show that BACEI-mediated processing of APP is affected in Rab11-silenced cells. Interestingly, whereas we see a significant reduction in C99 levels, C83 levels are increased. This could be due to an increased a cleavage of APP or C99 or could also represent a defect in g-secretase cleavage, demonstrating that Rab11-recycling endosomes play a crucial role in APP processing and Ap production. Indeed, Rab11 has been shown to interact with g-secretase component, PS (Dumanchinetal., 1999; Wakabayashi etal., 2009). However, we did not observe any influence of Rab11A on the activity or localization of g-secretase (data not shown).

APP endocytosis is mediated by the YENPTY cytosolic motif and is regulated by both cholesterol-dependent and clathrin-mediated endocytic pathways (Perez et al., 1999; Schneider et al., 2008). Similarly, endocytosis of BACE1 has been shown to be both clathrin dependent and clathrin independent via the ADP-ribosylation factor 6 pathway (Prabhu et al., 2012; San-nerud et al., 2011). So far, early endosomes, TGN, and the plasma membrane have been suggested to contribute to Ap production (Choy et al., 2012; Chyung and Selkoe, 2003; Rajendran et al., 2006; Sannerud et al., 2011). Although APP is known to be routed from endosomes to Golgi via the retromer and associated proteins (Andersen et al., 2005; Morel et al., 2013; Small and Gandy, 2006; Rogaeva et al., 2007; Small et al., 2005; Siegenthaler and Rajendran, 2012), nothing much is known about BACE1 recycling from endosomes.

Our results now identify the Rab11 -dependent slow recycling pathway as a trafficking route involved in Ap generation. A recent study showed that synaptic activity mediates the convergence of APP and BACE1 in acidic microdomains that colocalize with TfR (Das et al., 2013). Because this study did not look at colocalization of APP and BACE1 in Rab11 compartments and that a significant proportion of TfR is also found in early endosomes (Sonnichsen et al., 2000), the interaction most likely occurs in early endosomes because TfR is internalized from the plasma membrane to early endosomes and then is recycled to the plasma membrane via Rab11 -positive vesicles. Several studies suggest that early endosomes are the compartments where BACE1 cleaves APP, also in the neuronal context (Choy et al., 2012; Chyung and Selkoe, 2003; Rajendran et al., 2006; Sannerud et al., 2011). The fact that retromer-associated proteins or GGA3 regulates Ap levels is due to its involvement in sorting of APP or BACE1, respectively, from early endosomes and not recycling endosomes (Andersen et al., 2005; Morel et al., 2013; Siegenthaler and Rajendran, 2012; Tesco et al., 2007). Furthermore, early endosomes are acidic (Maxfield and Yamashiro, 1987), and recycling endosomes are not because they lack functional vacuolar ATPase (Gagescu et al., 2000; Schmidt and Haucke, 2007). In addition, we do not observe


(legend on next page)


Figure 7. A Road Map of APP Processing and Ap Production

Integrated map of the Rabs identified in the screen as regulators of APP processing and Ap production/secretion. Rabs indicated in green positively regulate Ap levels, and those indicated in red are negative regulators. Note that the majority of the Rabs regulate trafficking to and from early endosomes.

the p-cleaved ectodomain of APP in Rab11-positive compartments (Rajendran et al., 2006), suggesting that the compartments that Das et al. (2013) observed as stations where APP and BACE1 meet are most likely to be early endosomes and not recycling endosomes. So, how do recycling endosomes contribute to Ap generation? Our results now clearly show that mechanistically, Rab11-containing recycling endosomes

mediate the recycling of BACE1 to replenish the pool of BACE1 in early endosomes. In support of this latter notion, our time-lapse analysis shows dramatic alteration of BACE1 dynamics in cells expressing Rab11A DN mutant. In addition, we could clearly demonstrate that recycling of BACE1 from endosomes to the plasma membrane (for subsequent reinternaliza-tion) is severely impaired in the absence of functional Rab11

Figure 6. Rab11 Regulates the Surface Recycling of BACE1 and Is Essential for Maintenance of BACE1 Cell Surface Levels

(A) HeLa-swAPP cells were transfected with either control plasmids or the DN mutant of Rab11A and Flag-tagged BACE1. Cell surface levels of BACE1 were determined via FACS on nonpermeabilized cells using FLAG antibodies and Alexa 647-coupled secondary antibodies.

(B) The mean and the median intensity of the cell surface levels of BACE1 are lower in Rab11A DN-expressing cells.

(C) Microscopy of cell surface BACE1 on nonpermeabilized HeLa cells expressing BACE1 -Flag. Rab11A DN-expressing cells have marked decrease in cell surface BACE1.

(D) Immunofluorescence of cell surface BACE1 on nonpermeabilized primary neurons transfected with BACE1-Flag. Also in neurons, Rab11A DN-expressing cells have a marked decrease in cell surface BACE1.

(E) Recycling of BACE1 is significantly decreased in Rab11A DN-expressing cells. Cells were transfected with BACE-FLAG/Rab11A constructs (WT and DN) and incubated with Alexa 647-conjugated M1 FLAG primary antibodies for 30 min at 37°C, followed by washing and incubation with Alexa 488 secondary antibodies at 37°Cfor 30 min. This allows the primary antibody to bind the surface/cycling BACE1 and label theendosomal BACE population, and the secondary antibody to only bind the BACE1 that recycled to the surface. A ratio of the secondary to the primary gives the amount recycled in this time.

See also Figures S4F and S5B.


using both FACS and recycling assays. In addition, Rab17, another protein involved in the recycling of internalized cargo, also regulated sAPPp and Ap levels, thus underscoring the importance of recycling endosomes in APP processing.

Our screen and validation results uncover a trafficking route involved in Ap production. Because BACE1 cleavage of APP is critically involved in the pathogenesis of early-onset AD (Yang et al., 2003) and in certain forms of sporadic AD (Jonsson et al., 2012), we propose that the Rab11-mediated recycling route represents a drug target for AD, which is supported by our exome-sequencing results and the unbiased PPI network analysis. Interestingly, Eps15 homology domain-containing (EHD) proteins, which form complexes with Rab11 via Rab11-FIP2, were independently identified as critical regulators of dynamic BACE1 trafficking and axonal sorting in hippocampal neurons. Moreover, knockdown of EHD1 or EHD3 significantly reduced Ap levels in primary neurons (Buggia-Prevot et al., 2013). The network model suggests that the interaction of Bin1 with Rab11 is via Arf6, a known player in BACE1 endocytosis to early endosomal compartments (Sannerud et al., 2011), and GGA3, a protein that regulates early endosomal residency of BACE1, (Tesco et al., 2007) is also involved in the network, further supporting the link between AD risk and Rab11-mediated BACE1 endocytosis and recycling.

Taken together, our results clearly establish a link for recycling endosomes in BACE1 recycling, Ap generation, and AD and underscore the importance of systems level analysis in understanding the complexity of AD. An extended version of the Experimental Procedures can be found in the Supplemental Experimental Procedures.


Plasmidsencoding dsRed-tagged human WTRab11Aand DN mutant (S25N) (Choudhury et al., 2002) were purchased from Addgene. C-terminally EYFP-tagged mouse BACE1 was generated by subcloning BACE1 cDNA (provided by Nabil G. Seidah), in-frame into the pEYFP-N1 vector. HA-tagged Rab11A constructs have been described by Ren et al. (1998). The sequence corresponding to the Flag epitope in the BACE1-FLAG construct was introduced after the propeptide cleavage site within the luminal domain of mouse BACE1 using the following primers: 5'-CCGGGAGACCGACTACAAGGACGATGAT GACAAGGGGGGAGGATC-3' and 5'-CCGGGATCCTCCCCCCTTGTCATCA TCGTCCTTGTAGTCGGTCTC-3'.

siRNAs were purchased from Invitrogen (stealth siRNA). The sequences and the accession codes are supplied in Table S1.

RNAi Screen

RNAi screen was performed using HeLa cells expressing the Swedish APP mutation (HeLa-sweAPP). siRNAs were transfected with a final concentration of 5 nM using Oligofectamine (Invitrogen) as transfection reagent at a concentration of 0.3 ml in a total volume of 100 ml following manufacturer's instructions. Each siRNA transfection was performed in quadruplicate. After 24 hr, the transfection mix on the cells was replaced with fresh culture medium. At 69 hr after transfection, medium was again replaced with 100 ml fresh medium containing 10% Alamar blue (AbD Serotec). At 72 hr after transfection, Alamar blue measurements were taken using SpectraMAX GeminiXS (Molecular Devices) at an excitation wavelength of 544 nm and emission at 590 nm. Supernatant was collected and assayed for Ap and sAPPp. The cells in the transfected plate were lysed with 50 ml of lysis buffer for 20 min on ice.

RabGAP Screen

The RabGAP screen was performed in HeLa-sweAPP cells. Cells were seeded in 96-well plates at a density of 6,000 cells/well 1 day before transfection. Effectene (QIAGEN) was used as transfection reagent following manufacturer's instruction using 2.5 ml of Effectene and 0.8 ml of Enhancer in a total volume of 100 ml. Transfection mix was replaced with fresh medium after 3.5 hr. At 24 hr after transfection, medium was again replaced with fresh medium containing 10% Alamar blue. At 27 hr after transfection, Alamar blue measurements were taken using SpectraMAX GeminiXS at an excitation wavelength of 544 nm and emission at 590 nm. Supernatant was collected and assayed for Ap and sAPPp using the ECL assay (see Supplemental Experimental Procedures). The cells in the transfected plate were lysed with 30 ml of lysis buffer, incubated for 20 min on ice, and stored at —20°C.

Live-Cell Image Acquisition and Processing

Images were acquired on a motorized NikonTe2000 microscope equipped with a Cascade II:512 CCD Camera (Photometrics) using a 100x objective (NA 1.4). During live imaging, cells were maintained at 37°C in imaging medium (140 mM NaCl, 5 mM KCl, 3 mM CaCl2, 2 mM MgCl2,1.5 mM D-glucose, and 10 mM HEPES [pH 7.4]) in a custom-designed environment chamber. Time-lapse images were acquired at the rate of two frames/s. Images of fixed cells were acquired as 200 nm z stacks, deconvolved using Huygens software (Scientific Volume Imaging). Extended Depth of Field plugin of ImageJ software (National Institutes of Health) was used to generate single-plane projections from processed z stacks (Rasband, 1997-2012).

Recycling Assay

Cells were labeled with Alexa 647-conjugated M1 anti-FLAG for 30 min at 37°C, to allow antibodies to bind surface BACE1 and be internalized. Cells were washed twice in media, and incubated with Alexa 488-conjugated secondary antibodies for 30 min at 37°C, to detect labeled internalized receptors that recycled to the surface. Cells were fixed in 4% paraformaldehyde for 15 min, washed, mounted, and imaged. Cells were imaged using an Andor Revolution XD spinning disk system with a Nikon Eclipse Ti automated inverted microscope, using a 60x TIRF 1.49 NA objective. Images were acquired using an Andor iXon+ EM-CCD camera using Andor IQ with 488, 561, and 647 nm solid-state lasers as light sources, using identical parameters for all images. Confocal images were collected as tiff stacks and analyzed in ImageJ. All fluorescence quantitations were performed on images directly acquired from the camera with no manipulation or adjustments. To measure fluorescence, a region of interest was drawn around each cell and the mean fluorescence in each channel recorded. In each field, a region of the field without cells was chosen to estimate background. Percent recycling was calculated as the ratio of 488/647 fluorescence, after background correction. Statistical analyses were done using Microsoft Excel or GraphPad Prism (GraphPad Software).


Supplemental Information includes Supplemental Experimental Procedures, six figures, five tables, and two movies and can be found with this article online at


The members of the AESG (Alzheimer's Exome Sequencing Group) are Rita Guerreiro, Jose Bras, Celeste Sassi, J. Raphael Gibbs, Dena Hernandez, Michelle K. Lupton, Kristelle Brown, Kevin Morgan, John Powell, Andrew Singleton, and John Hardy.


L.R designed the research; V.U. performed all the RNAi, RabGAP screens, and validation experiments. B.S. and J.B. performed the ECL optimization assays. G.S. performed the optimization of siRNA transfection in mouse primary


neurons. V.B.-P. and G.T. performed plasmid cloning and live-cell Imaging experiments. M.S. provided reagents. N.R. performed the PPI network analysis of GWAS AD gene products. M.P. integrated all the data to curate the road map for APP processing. A.L.S. and M.A.P. performed and analyzed the recycling experiments. R.L.G., J.H., and the AESG group provided the exome-sequencing data on Rab11. L.R., V.U., V.B.-P., and G.T. analyzed the data. L.R. wrote the paper, and all the authors participated in the editing of the manuscript.


We thank G. Yu for the HeLa-swAPP cells, T.C. Südhof for the generous gift of Rab11 constructs, and F. Barrforthe generous gift of the RabGAP library. We thank M. Schwab, W. Annaert, H. Mohler, R. Nitsch, C. Hock, and the members of the L.R. Lab for critical input into the study. We thank R. Paolicelli for the help with statistics and E. Schwarz for help with the editing of the manuscript. L.R. acknowledges financial support from the Swiss National Science Foundation grant, the Novartis Foundation grant, the Velux Foundation, Bangerter Stiftung, Baugarten Stiftung, and the Synapsis Foundation. L.R. and V.U. acknowledge funding support from the European Neuroscience Campus of the Erasmus Mundus Program. G.S. was supported by an EMBO long-term fellowship and is a recipient of a Postdoc-Forschungskredit of the University of Zurich. G.T. acknowledges grant support from the National Institutes of Health (AG019070 and AG021495) and Cure Alzheimer's Fund. V.B.-P. was partially supported by a fellowship from Alzheimer's Disease Research Fund of Illinois Department of Public Health. This exome-sequencing work was supported in part by the Alzheimer's Research UK (ARUK), by an anonymous donor, by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium whose members are from the UCL/Institute of Neurology, the University of Sheffield and the MRC Protein Phosphorylation Unit at the University of Dundee, by the Big Lottery (to K.M.), and by a fellowship from ARUK to R.L.G.. The exome-sequencing component was also supported in part by the Intramural Research Programs of the National Institute on Aging and the National Institute of Neurological Disease and Stroke, National Institutes of Health, Department Of Health and Human Services Project number ZO1 AG000950-10. Some samples and pathological diagnoses were provided by the MRC London Neurodegenerative Diseases Brain Bank and the Manchester Brain Bank from Brains for Dementia Research, jointly funded from ARUK and AS via ABBUK Ltd.

Received: July 24, 2012 Revised: November 7, 2013 Accepted: December 3, 2013 Published: December 26, 2013


Andersen, O.M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C.A., Breiderhoff, T., Jansen, P., Wu, X., et al. (2005). Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 102, 13461-13466. Annaert, W., and De Strooper, B. (2002). A cell biological perspective on Alzheimer's disease. Annu. Rev. Cell Dev. Biol. 18, 25-51. Barr, F., and Lambright, D.G. (2010). Rab GEFs and GAPs. Curr. Opin. Cell Biol. 22, 461-470.

Borchelt, D.R., Thinakaran, G., Eckman, C.B., Lee, M.K., Davenport, F., Ratovitsky, T., Prada, C.M., Kim, G., Seekins, S., Yager, D., et al. (1996). Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/ 1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.

Buggia-Prevot, V., Fernandez, C.G., Udayar, V., Vetrivel, K.S., Elie, A., Roseman, J., Sasse, V.A., Lefkow, M., Meckler, X., Bhattacharyya, S., et al. (2013). A function for EHD family proteins in unidirectional retrograde dendritic transport of BACE1 and Alzheimer's disease Aß production. Cell Rep. 5, this issue, 1552-1563.

Cataldo, A.M., Peterhoff, C.M., Troncoso, J.C., Gomez-Isla, T., Hyman, B.T., and Nixon, R.A. (2000). Endocytic pathway abnormalities precede amyloid

beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157, 277-286.

Choudhury, A., Dominguez, M., Puri, V., Sharma, D.K., Narita, K., Wheatley, C.L., Marks, D.L., and Pagano, R.E. (2002). Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J. Clin. Invest. 109, 1541-1550. Choy, R.W., Cheng, Z., and Schekman, R. (2012). Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid ß (Aß) production in thetrans-Golgi network. Proc. Natl. Acad. Sci. USA 109, E2077-E2082. Chyung, J.H., and Selkoe, D.J. (2003). Inhibition of receptor-mediated endocy-tosis demonstrates generation of amyloid beta-protein at the cell surface. J. Biol. Chem. 278, 51035-51043.

Das, U., Scott, D.A., Ganguly, A., Koo, E.H., Tang, Y., and Roy, S. (2013). Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron 79, 447-460. De Strooper, B. (2010). Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 90, 465-494. Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., et al. (1996). Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710-713. Dumanchin, C., Czech, C., Campion, D., Cuif, M.H., Poyot, T., Martin, C., Charbonnier, F., Goud, B., Pradier, L., and Frebourg, T. (1999). Presenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport. Hum. Mol. Genet. 8, 1263-1269.

Ehehalt, R., Keller, P., Haass, C., Thiele, C., and Simons, K. (2003). Amyloido-genic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113-123.

Frasa, M.A., Koessmeier, K.T., Ahmadian, M.R., and Braga, V.M. (2012). Illuminating the functional and structural repertoire of human TBC/RABGAPs. Nat. Rev. Mol. Cell Biol. 13, 67-73.

Frisoni, G.B., Hampel, H., O'Brien, J.T., Ritchie, K., and Winblad, B. (2011). Revised criteria for Alzheimer's disease: what are the lessons for clinicians? Lancet Neurol. 10, 598-601.

Gagescu, R., Demaurex, N., Parton, R.G., Hunziker, W., Huber, L.A., and Gruenberg, J. (2000). The recycling endosome of Madin-Darby canine kidney cells is a mildly acidic compartment rich in raft components. Mol. Biol. Cell 11, 2775-2791.

Galvez, T., Gilleron, J., Zerial, M., and O'Sullivan, G.A. (2012). SnapShot: mammalian Rab proteins in endocytic trafficking. Cell 151, 234-234.e232. Haass, C., Koo, E.H., Mellon, A., Hung, A.Y., and Selkoe, D.J. (1992). Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357, 500-503. He, X., Li, F., Chang, W.P., and Tang, J. (2005). GGA proteins mediate the recycling pathway of memapsin 2 (BACE). J. Biol. Chem. 280, 11696-11703. Hsu, C., Morohashi, Y., Yoshimura, S., Manrique-Hoyos, N., Jung, S., Lauterbach, M.A., Bakhti, M., Gronborg, M., Möbius, W., Rhee, J., et al. (2010). Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A-C. J. Cell Biol. 189, 223-232.

Huang, Y., and Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.

Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012). A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99.

Kaether, C., Schmitt, S., Willem, M., and Haass, C. (2006). Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic 7, 408-415.

Kalvodova, L., Kahya, N., Schwille, P., Ehehalt, R., Verkade, P., Drechsel, D., and Simons, K. (2005). Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J. Biol. Chem. 280, 36815-36823.


Kametani, F., Usami, M., Tanaka, K., Kume, H., and Mori, H. (2004). Mutant presenilin (A260V) affects Rab8 in PC12D cell. Neurochem. Int. 44, 313-320. Kinoshita, A., Fukumoto, H., Shah, T., Whelan, C.M., Irizarry, M.C., and Hyman, B.T. (2003). Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J. Cell Sci. 116, 3339-3346.

Koo, E.H., and Squazzo, S.L. (1994). Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386-17389.

Laflamme, C., Assaker, G., Ramel, D., Dorn, J.F., She, D., Maddox, P.S., and Emery, G. (2012). Evi5 promotes collective cell migration through its Rab-GAP activity. J. Cell Biol. 198, 57-67.

Lichtenthaler, S.F. (2011). a-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. J. Neurochem. 116, 10-21. Lindsay, A.J., and McCaffrey, M.W. (2002). Rab11-FIP2 functions in transferrin recycling and associates with endosomal membranes via its COOH-terminal domain. J. Biol. Chem. 277, 27193-27199.

Longatti, A., Lamb, C.A., Razi, M., Yoshimura, S., Barr, F.A., and Tooze, S.A.

(2012). TBC1D14 regulates autophagosome formation via Rab11- and ULK1-positive recycling endosomes. J. Cell Biol. 197, 659-675.

Maxfield, F.R., and Yamashiro, D.J. (1987). Endosome acidification and the pathways of receptor-mediated endocytosis. Adv. Exp. Med. Biol. 225, 189-198.

Morel, E., Chamoun, Z., Lasiecka, Z.M., Chan, R.B., Williamson, R.L., Vetano-vetz, C., Dall'Armi, C., Simoes, S., Point Du Jour, K.S., McCabe, B.D., et al.

(2013). Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nat. Commun. 4, 2250.

Nitsch, R.M., Slack, B.E., Farber, S.A., Borghesani, P.R., Schulz, J.G., Kim, C., Felder, C.C., Growdon, J.H., and Wurtman, R.J. (1993). Receptor-coupled amyloid precursor protein processing. Ann. N Y Acad. Sci. 695, 122-127. Onodera, Y., Nam, J.M., Hashimoto, A., Norman, J.C., Shirato, H., Hashimoto, S., and Sabe, H. (2012). Rab5c promotes AMAP1-PRKD2 complex formation to enhance ß1 integrin recycling in EGF-induced cancer invasion. J. Cell Biol. 197, 983-996.

Ostrowski, M., Carmo, N.B., Krumeich, S., Fanget, I., Raposo, G., Savina, A., Moita, C.F., Schauer, K., Hume, A.N., Freitas, R.P., et al. (2010). Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19-30.

Perez, R.G., Soriano, S., Hayes, J.D., Ostaszewski, B., Xia, W., Selkoe, D.J., Chen, X., Stokin, G.B., and Koo, E.H. (1999). Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J. Biol. Chem. 274, 18851-18856.

Pfeffer, S., and Aivazian, D. (2004). Targeting Rab GTPases to distinct membrane compartments. Nat. Rev. Mol. Cell Biol. 5, 886-896. Prabhu, Y., Burgos, P.V., Schindler, C., Farias, G.G., Magadan, J.G., and Bonifacino, J.S. (2012). Adaptor protein 2-mediated endocytosis of the ß-sec-retase BACE1 is dispensable for amyloid precursor protein processing. Mol. Biol. Cell 23, 2339-2351.

Rajendran, L., and Annaert, W. (2012). Membrane trafficking pathways in Alzheimer's disease. Traffic 13, 759-770.

Rajendran, L., Honsho, M., Zahn, T.R., Keller, P., Geiger, K.D., Verkade, P., and Simons, K. (2006). Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. USA 103, 11172-11177.

Rajendran, L., Schneider, A., Schlechtingen, G., Weidlich, S., Ries, J., Braxmeier, T., Schwille, P., Schulz, J.B., Schroeder, C., Simons, M., et al. (2008). Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science 320, 520-523.

Ren, M.,Xu, G., Zeng, J., De Lemos-Chiarandini, C., Adesnik, M., and Sabatini, D.D. (1998). Hydrolysis of GTP on rab11 is required for the direct delivery of

transferrin from the pericentriolar recycling compartment to the cell surface but not from sorting endosomes. Proc. Natl. Acad. Sci. USA 95, 6187-6192. Rogaeva, E., Meng, Y., Lee, J.H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C.T., Cheng, R., Hasegawa, H., et al. (2007). The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39, 168-177.

Sannerud, R., Declerck, I., Peric, A., Raemaekers, T., Menendez, G., Zhou, L., Veerle, B., Coen, K., Munck, S., De Strooper, B., et al. (2011). ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1. Proc. Natl. Acad. Sci. USA 108, E559-E568.

Schlüter, O.M., Schmitz, F., Jahn, R., Rosenmund, C., and Südhof, T.C. (2004). A complete genetic analysis of neuronal Rab3 function. J. Neurosci. 24, 66296637.

Schmidt, M.R., and Haucke, V. (2007). Recycling endosomes in neuronal membrane traffic. Biol. Cell 99, 333-342.

Schneider, A., Rajendran, L., Honsho, M., Gralle, M., Donnert, G., Wouters, F., Hell, S.W., and Simons, M. (2008). Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J. Neurosci. 28, 2874-2882.

Schuldiner, M., Collins, S.R., Thompson, N.J., Denic, V., Bhamidipati, A., Punna, T., Ihmels, J., Andrews, B., Boone, C., Greenblatt, J.F., et al. (2005). Exploration of the function and organization of the yeast early secretory pathway through an epistatic miniarray profile. Cell 123, 507-519. Seabra, M.C., Mules, E.H., and Hume, A.N. (2002). Rab GTPases, intracellular traffic and disease. Trends Mol. Med. 8, 23-30.

Selkoe, D.J. (2011a). Alzheimer's disease. Cold Spring Harb. Perspect. Biol. 3, a004457.

Selkoe, D.J. (2011b). Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17, 1060-1065.

Selkoe, D.J., and Wolfe, M.S. (2007). Presenilin: running with scissors in the membrane. Cell 131, 215-221.

Shiba, T., Koga, H., Shin, H.W., Kawasaki, M., Kato, R., Nakayama, K., and Wakatsuki, S. (2006). Structural basis for Rab11-dependent membrane recruitment of a family of Rab11-interacting protein 3 (FIP3)/Arfophilin-1. Proc. Natl. Acad. Sci. USA 103, 15416-15421.

Siegenthaler, B.M., and Rajendran, L. (2012). Retromers in Alzheimer's disease. Neurodegener. Dis. 10, 116-121.

Small, S.A., and Gandy, S. (2006). Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron 52, 15-31.

Small, S.A., Kent, K., Pierce, A., Leung, C., Kang, M.S., Okada, H., Honig, L., Vonsattel, J.P., and Kim, T.W. (2005). Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann. Neurol. 58, 909-919. Sonnichsen, B., De Renzis, S., Nielsen, E., Rietdorf, J., and Zerial, M. (2000). Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. J. Cell Biol. 149, 901-914.

Spasic, D., and Annaert, W. (2008). Building gamma-secretase: the bits and pieces. J. Cell Sci. 121, 413-420.

Stenmark, H., and Olkkonen, V.M. (2001). The Rab GTPase family. Genome Biol. 2, REVIEWS3007.

Szodorai, A., Kuan, Y.H., Hunzelmann, S., Engel, U., Sakane, A., Sasaki, T., Takai, Y., Kirsch, J., Müller, U., Beyreuther, K., et al. (2009). APP anterograde transport requires Rab3A GTPase activity for assembly of the transport vesicle. J. Neurosci. 29, 14534-14544.

Tesco, G., Koh, Y.H., Kang, E.L., Cameron, A.N., Das, S., Sena-Esteves, M., Hiltunen, M., Yang, S.H., Zhong, Z., Shen, Y., et al. (2007). Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 54, 721-737.

Thinakaran, G., and Koo, E.H. (2008). Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615-29619.


Tisdale, E.J. (2003). Rab2 interacts directly with atypical protein kinase C (aPKC) iota/lambda and inhibits aPKCiota/lambda-dependent glyceralde-hyde-3-phosphate dehydrogenase phosphorylation. J. Biol. Chem. 278, 52524-52530.

Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., et al. (1999). Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.

Vassar, R., Kovacs, D.M., Yan, R., and Wong, P.C. (2009). The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J. Neurosci. 29, 12787-12794. von Arnim, C.A., Spoelgen, R., Peltan, I.D., Deng, M., Courchesne, S., Koker, M., Matsui, T., Kowa, H., Lichtenthaler, S.F., Irizarry, M.C., and Hyman, B.T. (2006). GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing. J. Neurosci. 26, 9913-9922.

Wakabayashi, T., Craessaerts, K., Bammens, L., Bentahir, M., Borgions, F., Herdewijn, P., Staes, A., Timmerman, E., Vandekerckhove, J., Rubinstein, E., et al. (2009). Analysis of the gamma-secretase interactome and validation

of its association with tetraspanin-enriched microdomains. Nat. Cell Biol. 11, 1340-1346.

Wilcke, M., Johannes, L., Galli, T., Mayau, V., Goud, B., and Salamero, J. (2000). Rab11 regulates the compartmentalization of early endosomes required for efficient transport from early endosomes to the trans-golgi network. J. Cell Biol. 151, 1207-1220.

Willem, M., Lammich, S., and Haass, C. (2009). Function, regulation and therapeutic properties of beta-secretase (BACE1).Semin. Cell Dev. Biol. 20,175-182.

Yang, L.B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003). Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9, 3-4.

Yoshimura, S., Egerer, J., Fuchs, E., Haas, A.K., and Barr, F.A. (2007). Functional dissection of Rab GTPases involved in primary cilium formation. J. Cell Biol. 178, 363-369.

Zerial, M., and McBride, H. (2001). Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol. 2, 107-117.